Use of Prazosin for Pediatric PTSD-Associated Nightmares and Sleep Disturbances: A Retrospective Chart Review
Open Access
- 28 July 2017
- journal article
- review article
- Published by Springer Nature in Neurology and Therapy
- Vol. 6 (2) , 247-257
Abstract
Introduction Youth exposed to trauma have an increased risk for developing posttraumatic stress disorder (PTSD) and associated sleep disturbances and nightmares. The alpha-1 antagonist prazosin reduces sleep disturbances and nightmares in adults with PTSD; however, its use in youth with PTSD has not been systematically evaluated. We retrospectively examined the tolerability and clinical outcomes associated with prazosin treatment in youth with PTSD-related nightmares and dysomnias. Method A retrospective chart review identified youth with PTSD (N = 40) treated with prazosin between 2014 and 2016 in a trauma clinic. We assessed the UCLA PTSD Reaction Index for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition scores (and sub-scores for intrusive, hyperarousal, avoidant and negative cognition/mood symptoms) and sleep scale, as well as adverse events and vital signs. Linear mixed effects models were utilized to evaluate the change in symptom severity, and vital signs were monitored throughout treatment. Result Follow-up data were available for 34 patients with PTSD (mean age 13.4 ± 2.9 years, 82% female), of whom 76% had a history of sexual abuse and 65% had at least one comorbid psychiatric disorder. The mean duration of prazosin treatment was 10.2 ± 8.1 (range 2–30) weeks, and the mean number of follow-up visits was 3 ± 1.23. Of these 34 patients, 79% received trauma-focused cognitive behavioral therapy. The dose range of prazosin was 1–15 mg at every bedtime (0.02–0.3 mg/kg), with 35% receiving ≥5 mg/day. Treatment-emergent side effects were reported by 26% (n = 8) of patients, including dizziness (18%), anxiety (9%) and headaches (6%). Prazosin treatment was associated with improved sleep and nightmares over time (pre-treatment 7.3 ± 0.9, post-treatment 3.1 ± 2.4; p < 0.001). Conclusion Prazosin was well-tolerated and associated with improvements in nightmares and sleep in youth with PTSD. Adverse events were consistent with the known side-effect profile of prazosin and included dizziness and nausea.Keywords
Funding Information
- Substance Abuse and Mental Health Services Administration (1U79SM080000-01)
This publication has 47 references indexed in Scilit:
- Sleep Disturbance in Pediatric PTSD: Current Findings and Future DirectionsJournal of Clinical Sleep Medicine, 2013
- Treatment of Nightmares With Prazosin: A Systematic ReviewMayo Clinic Proceedings, 2012
- Sertraline Treatment of Children and Adolescents With Posttraumatic Stress Disorder: A Double-Blind, Placebo-Controlled TrialJournal of Child and Adolescent Psychopharmacology, 2010
- Psychopharmacologic Treatment of Posttraumatic Stress Disorder in Children and AdolescentsThe Journal of Clinical Psychiatry, 2010
- Preliminary Findings Concerning the Use of Prazosin for the Treatment of Posttraumatic Nightmares in a Refugee PopulationJournal of Psychiatric Practice, 2009
- Meta-Analysis: Treatment of Attention-Deficit/Hyperactivity Disorder in Children With Comorbid Tic DisordersJournal of the American Academy of Child & Adolescent Psychiatry, 2009
- Development and Validation of a Measure of Adolescent Dissociation: The Adolescent Dissociative Experiences ScaleJournal of Nervous & Mental Disease, 1997
- The Screen for Child Anxiety Related Emotional Disorders (SCARED): Scale Construction and Psychometric CharacteristicsJournal of the American Academy of Child & Adolescent Psychiatry, 1997
- Clonidine for Posttraumatic Stress Disorder in Preschool ChildrenJournal of the American Academy of Child & Adolescent Psychiatry, 1996
- First dose hypotension with enalapril and prazosin in congestive heart failureInternational Journal of Cardiology, 1991